MedTrace Logo

Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements

NCT01745198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 121

Last updated 2015-04-28

No results posted yet for this study

Summary

In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition. The purpose of the current study is to expand the retrospective study dataset by prospectively collecting additional biomarker and imaging data.

Conditions

Sponsors & Collaborators

  • The Shankle Clinic

    collaborator UNKNOWN

  • Hoag Memorial Hospital Presbyterian

    collaborator OTHER

  • Pamlab, Inc.

    lead INDUSTRY

Principal Investigators

  • William R Shankle, MS, MD, FACP · Shankle Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-03-31
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01745198 on ClinicalTrials.gov